Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Dynavax Technologies Slid 19% in December

By Cory Renauer - Updated Apr 14, 2019 at 8:54PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors worried disappointing vaccine sales won't improve in 2019 sent the stock tumbling.

What happened

Shares of Dynavax Technologies ( DVAX 0.87% ), a small biopharmaceutical company struggling to launch a new hepatitis B vaccine and develop a new cancer therapy, fell 19% in December, according to data from S&P Global Market Intelligence. It was a quiet month for Dynavax, but a general market panic dragged the Nasdaq Biotechnology Index 11% lower. 

Check out the latest Dynavax Technologies earnings call transcript.

So what 

Dynavax is more sensitive to market pressure than its peers right now because its first drug launch isn't going very well. The FDA approved Heplisav-B in 2017, but sales during the first nine months of 2018 tallied just $2.9 billion.

Person in a suit drawing a downward sloping chart.

Image source: Getty Images.

The company has an experimental new cancer therapy in development that produced impressive tumor response data early on, but mixed results from an ongoing study are making investors nervous.

Now what

Independent drug launches generally don't perform as well as those with big pharma backing, but Hepislav-B is showing signs of life. Sales in October exceeded the entire first nine months of 2018.

Investors probably don't want to let go of these shares until we hear what the CEO has to say about the year ahead on Thursday, Jan. 10, at the J.P. Morgan Healthcare conference.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dynavax Technologies Corporation Stock Quote
Dynavax Technologies Corporation
DVAX
$16.21 (0.87%) $0.14
Nasdaq, Inc. Stock Quote
Nasdaq, Inc.
NDAQ
$206.61 (-1.18%) $-2.47

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
673%
 
S&P 500 Returns
142%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.